Blanket Purchase Agreement 36F79722D0165-36E79724A0015
Award Date
4/30/24
Last Date to Order
4/29/26
Federal Agency
National Acquisition Center
Awardee
Ardelyx, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
Ardelyx, Inc., a for-profit pharmaceutical company, has been awarded multiple federal contract Indefinite Delivery Vehicles (IDVs) from the U.S. Department of Veterans Affairs (VA) to provide specialized pharmaceutical products, primarily the drug XPHOZAH (tenapanor), to support the healthcare needs of military veterans. The key contracts include a $32,500,000 Blanket Purchase Agreement (BPA) and a $300,000 Federal Supply Schedule (FSS-61-IB) contract, both of which enable Ardelyx to efficiently...
The U.S. Department of Veterans Affairs (VA) has awarded a Blanket Purchase Agreement (BPA) worth up to $2,500,000 to Amneal Pharmaceuticals of New York, LLC, a for-profit limited liability company that manufactures pharmaceutical products. The BPA is for the provision of the generic drug sodium oxybate, which is used to treat narcolepsy. Amneal Pharmaceuticals holds several indefinite delivery vehicle (IDV) contracts with federal agencies, including a 5-year, $1,700,000 Federal Supply...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Amryt Pharmaceuticals Inc., a foreign-owned, for-profit organization, on November 5, 2022. The potential value of the BPA is $1,000,000. No set-aside was used. The BPA is for a single award and permits ordering of Mycapssa, Juxtapid, and Myalept through March 14, 2024. Mycapssa, Juxtapid, and Myalept are pharmaceutical products used to treat certain rare diseases. The Department of...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Akebia Therapeutics, Inc. as a single-award contract under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The BPA has a ceiling value of $10,254,764.65 and a period of performance from April 25, 2025 to April 24, 2026. The purpose of this BPA is to provide the VA with the pharmaceutical products VAFSEO and AURYXIA. No set-asides were used for this award....
The Department of Veterans Affairs awarded a multiple-award federal supply schedule contract to Amryt Pharmaceuticals Inc. with a potential value of $225,000. The schedule is for pharmaceuticals and hematology-related products under contract number 65 IB. This enables ordering through September 2028. Additionally, the Department of Veterans Affairs National Acquisition Center awarded a single-award blanket purchase agreement to Amryt Pharmaceuticals with a value of up to $1,000,000. The BPA...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Nobelpharma America, LLC, a foreign-owned, self-certified small disadvantaged business. The single-award BPA, valued at up to $4.5 million, is for the delivery of the medication HYFTOR through June 2026. HYFTOR is likely used to treat conditions like post-traumatic stress disorder and chronic pain among veterans. In addition to this BPA, Nobelpharma America, LLC...
This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian agency, to Otsuka America Pharmaceutical Inc., a large pharmaceutical manufacturer. The $83,342,090.00 BPA is for the supply of the drug Jynarque (tolvaptan) to the Department of Veterans Affairs (VA) healthcare system. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule...
The U.S. Department of Veterans Affairs (VA) has awarded a single-award Blanket Purchase Agreement (BPA) to Ferring Pharmaceuticals Inc., a for-profit manufacturer of pharmaceutical goods, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The $5.96 million BPA, with a period of performance through March 2026, enables the VA to procure the drug Adstiladrin (nadofaragene firadenovec), a treatment for genitourinary cancers, to support the provision of healthcare services to...
The Department of Veterans Affairs awarded a Federal Supply Schedule contract to Vyera Pharmaceuticals, LLC to procure drugs, pharmaceuticals, and related hematology products. The potential value of this multiple award schedule is $3.5 million with an ordering period through September 2029. Additionally, the National Acquisition Center established a single award Blanket Purchase Agreement with Vyera Pharmaceuticals on behalf of the Veterans Health Administration. Valued at $450,000, this BPA...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs National Acquisition Center to Idorsia Pharmaceuticals US Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and related products. The $3.1 million single-award contract establishes an Indefinite Delivery Vehicle (IDV) for the procurement of orexin inhibitors, a class of sleep-regulating medications, over a one-year base period with four option years. This BPA aims to ensure the availability of...